TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
17.740
+0.470 (+2.721%)
As of 2:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.270
Open17.320
Bid17.750 x 2600
Ask17.760 x 1400
Day's Range17.080 - 17.795
52 Week Range10.850 - 33.820
Volume6,969,743
Avg. Volume12,635,217
Market Cap18.039B
Beta1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble
    Yahoo Finance Video7 days ago

    MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: These are the top risks CEOs are citing this earnings season
    Yahoo Finance Video10 days ago

    MARKETS: These are the top risks CEOs are citing this earnings season

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: Welcome to the low volume, low liquidity algo-driven market
    Yahoo Finance Video16 days ago

    MARKETS: Welcome to the low volume, low liquidity algo-driven market

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Teva to reduce size of board after June shareholders meeting
    Reuters10 hours ago

    Teva to reduce size of board after June shareholders meeting

    Three directors are stepping down from the board at Teva Pharmaceutical Industries (TEVA.TA) (TEVA.N) and only one new director is being nominated to replace them, the company said on Thursday. Israel-based Teva, the world's largest generic drugmaker, is in the midst of an overhaul to deal with the $35 billion of debt it amassed after buying Allergan’s Actavis generic drug business for $40.5 billion in 2016. Analysts and investors have criticized the company's management and board of directors for overpaying for this deal.

  • TheStreet.com20 hours ago

    Aceto's Search for Deal May Be Slowed by DOJ Subpoena

    has received a subpoena from the Justice Department as part of its investigation of the generic sector, making any sale more problematic. The company, which is considering strategic alternatives, revealed the DOJ news in a filing with the Securities and Exchange Commission on Monday, April 23. Aceto sought to walk a fine line as it made investors aware of DOJ's action while at the same time making it sound like business as usual.

  • Reuters2 days ago

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters2 days ago

    Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters2 days ago

    FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Mylan NV Still Undervalued Despite Unveiling of New Products
    InvestorPlace3 days ago

    Mylan NV Still Undervalued Despite Unveiling of New Products

    Mylan NV (NASDAQ:MYL), while still trending upward on the stock market, is on pause and without direction at the moment. Markets do not yet recognize the growth potential in MYL stock. It produces the global supply of EpiPens for Mylan, but has manufacturing problems at its Missouri plant.

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist3 days ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.

  • Teva, Procter & Gamble to dissolve OTC partnership.
    American City Business Journals7 days ago

    Teva, Procter & Gamble to dissolve OTC partnership.

    The joint venture called PGY Healthcare sells OTC product in more than 50 countries outside North America. The company will terminate operations on July 1.

  • Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
    Market Realist7 days ago

    Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

    Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.

  • P&G sales, earnings per share climb
    American City Business Journals7 days ago

    P&G sales, earnings per share climb

    “We delivered modest top- and bottom-line growth in a challenging macro environment in the third quarter,” CEO David Taylor said.

  • Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
    Market Realist8 days ago

    Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.

  • Jazz Pharmaceuticals: How It’s Positioned before 1Q18
    Market Realist8 days ago

    Jazz Pharmaceuticals: How It’s Positioned before 1Q18

    In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist8 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist9 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
    InvestorPlace10 days ago

    Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out

    At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.

  • Reuters11 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.

  • Reuters11 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva, the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool13 days ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Investopedia13 days ago

    8 Contrarian Stock Picks for a Rocky Market: CS

    Analysts recommend such unpopular names as Ralph Lauren and Teva Pharmaceuticals.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist13 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Are Drug Prices Too Low?
    Bloomberg15 days ago

    Are Drug Prices Too Low?

    Generic makers say they may stop making medicines that don’t turn a profit.